Selumetinib

Potent and selective ATP non-competitive inhibitor of MEK1/2

Selumetinib (AZD6244) is a second-generation, orally available, potent and selective ATP non-competitive inhibitor of MEK 1/2. In direct assays, AZD6244 selectively inhibits purified active MEK1 and MEK2 with an IC50 of 14 nM, and AZD6244 has reported IC $_{50}$ values of <100nm for MEK1 in ELISA assays and in bindings assays against recombinant domains of MEK2, Kd values were 53nM for AZD6244. AZD6244 demonstrated very effective anti-proliferation effects against several different cell lines with IC50 values ranging from a low of 3nM to < 1 μ M depending upon the cell system used, and the compound inhibits basal and growth factor-stimulated phosphorylation of ERK1/ 2 with IC $_{50}$ concentrations < 40 nM. AZD6244 has demonstrated potent dose-dependent antitumor activity against a panel of mouse xenograft models of colorectal, pancreatic, liver, skin, and lung cancer, and inhibition of tumor growth was found to correlate with the reduction of phospho-ERK1/2 levels in tumors.

Citations: 1

View Online »

Ordering Information


Order Online »

ENZ-CHM184-0050

50mg

Manuals, SDS & CofA

View Online »



Handling & Storage

Use/Stability As indicated on product label or CoA when stored as recommended.

Short Term Storage +4°C

Long Term Storage -20°C

Shipping Ambient Temperature

Regulatory Status RUO - Research Use Only

Product Details

Alternative Name AZD-6244, ARRY-142886

Appearance Beige powder.

CAS 606143-52-6

Couple Target MEK

Couple Type Inhibitor

Formula $C_{17}H_{15}BrClFN_4O_3$

Identity Determined by EM-MS.

MW 457.7

Purity ≥95% (HPLC)

Solubility Soluble in DMSO (92mg/ml) or ethanol (<1mg/ml).

eu@enzolifesciences.com